Research what you see: Antimicrobial resistance and pathogenesis
|
|
- Gerard Myles May
- 5 years ago
- Views:
Transcription
1 Research what you see: Antimicrobial resistance and pathogenesis Director, Mycology Research Unit and XDR Pathogen Laboratory University of Pittsburgh Cornelius J. Clancy, M.D. Chief, Infectious Diseases VA Pittsburgh Healthcare System NIAID/IDSA Infectious Diseases Research Career Meeting Bethesda, MD June 5, 2015
2 2
3 3 Allow myself to introduce myself
4 4 Allow myself to introduce myself
5 Candida infections Oropharyngeal candidiasis Candidemia Asmundsdottir J Clin MIcrobiol Rex NEJM 1994
6 What kinds of candidiasis are we seeing? Case reports Case series Clin Infect Dis
7 What kinds of candidiasis are we seeing? Case reports Case series Clin Infect Dis 1997 Why do patients fail antifungal treatment? Clinical studies In vitro susceptibility testing AAC
8 What kinds of candidiasis are we seeing? Case reports Case series Clin Infect Dis 1997 Why do patients fail antifungal treatment? Clinical studies In vitro susceptibility testing AAC 1999 How do Candida become resistant? How do they cause different infections? 8 Molecular biology Animal models DC, OPC, VVC Infect Immun 2003
9 IDSA Fellowship in Medical Mycology NIH KO8 Career Development Award (VA Career Development Award) 9
10 10
11 A case Case from 1 UPMC A 64 year-old man underwent right extended hepatectomy with roux en y biliary reconstruction for a non-malignant hepatic mass His post-operative course was complicated by biliary leak abscess s/p stent and ex-lap drainage, which revealed E. coli and VRE He underwent repeat laparotomies at 4 and 8 weeks after the hepatectomy
12
13 A case Case from 1 UPMC Abscess cultures at both times revealed C. glabrata and VRE Blood cultures negative He received 2 x 4 week courses of micafungin He developed septic shock Blood culture positive for C. glabrata He was treated with LFAB, but died
14 What is likelihood that this C. glabrata is echinocandin resistant? a. 0-5% b. 8-18% c. ~50% d. ~80% e. Almost 100% A case from UPMC
15 Echinocandins Inhibit β-1,3-glucan synthase Fungicidal in vitro; prolonged PAFE Induce Candida apoptosis Promote phagocytosis via Dectin-1 Highly active against C. albicans, C. glabrata, C. tropicalis, C. krusei Potential hole: C. parapsilosis ( MICs, significance?) Parenteral only Linear PK; amenable to dose-escalation Extremely high protein binding Penetration limited into urine, CNS, ocular fluid Excellent safety profile
16 Echinocandin resistance Garcia-Effron AAC 2008
17 Candida FKS mutant Candida Pittsburgh ( ) 8% FKS mutant C. glabrata Shields AAC 2012, 2013; Shields 2015 Houston ( ) 18% FKS mutant C. glabrata Beyda CID 2014 Duke ( ) 8% FKS mutant C. glabrata Alexander CID 2013 FKS mutations are rare among other spp. C. albicans 1-5% Castanheira AAC 2010; Shields ICAAC 2014, 2015 C. tropicalis, C. krusei Castanheira AAC 2010; Prigitano New Microbiol 2014; Jensen AAC 2014; Jensen AAC 2013; Garcia-Effron AAC 2010 C. parapsilosis not reported (intrinsic polymorphism) Prior echinocandin exposure is the key risk factor Duration of exposure (64 days median (range:3-188)) Exposure within 30 days>60 days>90 days
18 Candida FKS mutant Candida Pittsburgh ( ) 8% FKS mutant C. glabrata Shields AAC 2012, 2013; Shields 2015 Houston ( ) 18% FKS mutant C. glabrata Beyda CID 2014 Duke ( ) 8% FKS mutant C. glabrata Alexander CID 2013 FKS mutations are rare among other spp. C. albicans 1-5% Castanheira AAC 2010; Shields ICAAC 2014, 2015 C. tropicalis, C. krusei Castanheira AAC 2010; Prigitano New Microbiol 2014; Jensen AAC 2014; Jensen AAC 2013; Garcia-Effron AAC 2010 C. parapsilosis not reported (intrinsic polymorphism) Prior echinocandin exposure is the key risk factor Duration of exposure (64 days median (range:3-188)) Exposure within 30 days>60 days>90 days 50% C. glabrata FKS mutants
19 What is likelihood that this C. glabrata is echinocandin resistant? a. 0-5% b. 8-18% c. ~50% d. ~80% e. Almost 100% A case from UPMC C. glabrata bloodstream isolate FKS2 F659del mutant Micafungin MIC=2 µg/ml Caspofungin MIC=1 µg/ml (YeastOne)
20 What is likelihood that this C. glabrata is echinocandin resistant? a. 0-5% b. 8-18% c. ~50% d. ~80% e. Almost 100% A case from UPMC C. glabrata bloodstream isolate FKS2 F659del mutant Micafungin MIC=2 µg/ml Caspofungin MIC=1 µg/ml (YeastOne) What does this mean?
21 Echinocandin susceptibility testing Reference broth microdilution (BMD) methods CLSI M27-A3 EUCAST Edef7.2 Revised Echinocandin interpretive clinical breakpoint (CBP) MICs MIC distributions Epidemiologic cut-off values Mechanisms of resistance PK/PD parameters Correlation with clinical outcomes Pfaller AJM
22 Echinocandin CBP MICs Candida spp. Agent CLSI breakpoint MICS EUCAST breakpoint MICs Susceptible Intermediate Resistant Susceptible Resistant C. albicans Anidulafungin Caspofungin Micafungin 0.25 µg/ml 0.25 µg/ml 0.25 µg/ml 0.5 µg/ml 0.5 µg/ml 0.5 µg/ml >0.5 µg/ml >0.5 µg/ml >0.5 µg/ml 0.03 µg/ml Not proposed µg/ml >0.03 µg/ml Not proposed >0.016 µg/ml C. glabrata Anidulafungin Caspofungin Micafungin µg/ml µg/ml 0.06 µg/ml 0.25 µg/ml 0.25 µg/ml µg/ml >0.25 µg/ml >0.25 µg/ml >0.125 µg/ml 0.06 µg/ml Not proposed 0.03 µg/ml >0.06 µg/ml Not proposed >0.03 µg/ml C. tropicalis, C. krusei Anidulafungin Caspofungin Micafungin 0.25 µg/ml 0.25 µg/ml 0.25 µg/ml 0.5 µg/ml 0.5 µg/ml 0.5 µg/ml >0.5 µg/ml >0.5 µg/ml >0.5 µg/ml 0.06 µg/ml Not proposed Not proposed >0.06 µg/ml Not proposed Not proposed C. parapsilosis Anidulafungin Caspofungin Micafungin 2 µg/ml 2 µg/ml 2 µg/ml 4 µg/ml 4 µg/ml 4 µg/ml >4 µg/ml >4 µg/ml >4 µg/ml µg/ml Not proposed µg/ml >4 µg/ml Not proposed >2 µg/ml
23 Reference BMD: Issue 1 Inter-laboratory variability of caspofungin MICs 24 international labs Modal variability of 4-5 dilutions in caspofungin MICs vs. C. albicans, C. glabrata, C. tropicalis and C. krusei. CLSI caspofungin CBPs could lead to reporting an excessive number of wild-type isolates as resistant Espinell-Ingroff AAC 2013
24 Over-calling caspofungin non-susceptibility Number of Isolates Number of Isolates Number of Isolates C. glabrata (n=115) C. albicans (n=39), C. krusei (n=10), C. tropicalis (n=10) C. parapsilosis (n=41) Shields AAC 2012, 2013, ICAAC
25 Reference BMD: Issue 2 Clinical microbiology labs do not use it Commercial antifungal susceptibility testing methods in the U.S. (CAP Proficiency testing program, 2013) 4% 12% 40% Vitek 2 12% Yeast One Other Etest Disk diffusion 32% Pfaller, CLSI 2014 Survey of 15 large U.S. tertiary care centers, % (8/15) performed routine echinocandin susceptibility testing of Candida BSI All except one used Sensititre Yeast One Eschenauer AAC 2014
26 Real-world echinocandin testing 9 U.S., Australian, N.Z. hospitals, Eschenauer AAC 2014
27 Real-world echinocandin testing 9 U.S., Australian, N.Z. hospitals, Eschenauer AAC 2014 Non-susceptibility rates using CLSI CBPs Candida spp Agent(s) % Resist % Intermed. C. albicans, C. parap., C. tropicalis A, C, M 1.4% 3% C. glabrata A 6.1% 2.1% C 5.9% 17.8% M 7.5% 4.3% C. krusei A 0% 9.4% C 5.6% 46.5% M 2.5% 2.5% Most are not FKS mutants
28 Reference BMD: Issue 3 Unclear clinical relevance Kartsonis AAC 2005
29 Reference BMD: Issue 3 Unclear clinical relevance Kartsonis AAC 2005 C. albicans, krusei, tropicalis C. parapsilosis
30 Caspofungin CBP and C. glabrata candidemia outcomes Variable CLSI CBP >0.125 µg/ml CLSI CBP >0.25 µg/ml ROC CBP >0.5 µg/ml % sensitivity % specificity LR 95% 4% NA 95% 17% NA 60% 86% 4.3 Shields AAC 2012; ICAAC 2014 Optimal performance with Etest or YeastOne Caspofungin MIC >0.25 µg/ml Shields AAC 2013; ICAAC 2014
31 Risk factors for echinocandin treatment failure Variable Univariate (p) Multivariate (p) Pittsburgh Houston Pittsburgh Houston GI disease/ surgery 0.03 < Renal dysfnc N/D 0.04 Prior EC <0.01 <0.01 Caspo MIC* FKS mutant *Pitt: >0.25 µg/ml (YO) Houston: >0.125 µg/ml (YO) Shields AAC 2012 Beyda CID 2014
32 Algorithm for predicting C. glabrata candidemia treatment responses FKS mutants Shields AAC 2013
33 Algorithm for predicting C. glabrata candidemia treatment responses Shields AAC 2013
34 Variable Anidulafungin Micafungin MIC LR MIC LR CLSI CBP* >0.12 µg/ml 10 >0.06 µg/ml 2.4 ROC CBP >0.06 µg/ml 14 >0.03 µg/ml 4 ET, YO CBP >0.06 µg/ml 8 >0.03 µg/ml 8 *Intermediate CBP Shields AAC 2013 Our experience supports EUCAST anidulafungin and micafungin CBPs for C. glabrata
35 Algorithm for predicting C. glabrata candidemia treatment responses Shields AAC 2013
36 Conclusions (1) Echinocandins are emerging as agents of first choice against most cases of invasive candidiasis Agents are considered interchangeable Emergence of echinocandin-resistant C. glabrata with breakthrough or prior exposure (but keep it in perspective)
37 Conclusions (1) FKS mutations are pretty hard to induce in the clinic Never seen without prior exposure Very rarely encountered in non-c. glabrata spp. C. glabrata generally require prolonged exposure Wild-type FKS despite 80+ days of prior exposure Most treatment failures are not due to microbiologic resistance Host factors, biofilms, local PK, persistent foci, etc.
38 Echinocandin susceptibility testing may be a useful management tool in certain cases In patients with prior exposure, in whom you want or need to use an EC Treatment failures Routine susceptibility testing is important for epidemiologic purposes and surveillance for resistance Caspofungin MICs and CBPs by reference method are not reliable Yeast One Conclusions (1) Clinical breakpoints for all agents still need tweaking
39 A case from UPMC: Epilogue C. glabrata isolates from intra-abdominal abscesses (IAA) were not tested for echinocandin susceptibility at the time The second IAA isolate was shown to be FKS2 F659del mutant Micafungin MIC=2 µg/ml, Caspofungin MIC=1µg/mL (same as bloodstream isolate)
40 Types Types of of invasive candidiasis (IC) 1. Candidemia Candidemia with deepseated candidiasis (DSC) Clancy and Nguyen Clin Infect Dis 2013
41 Types Types of of invasive candidiasis (IC) 1. Candidemia Candidemia with deepseated candidiasis (DSC) 3. DSC without candidemia Clancy and Nguyen Clin Infect Dis 2013
42 What is our experience with IAC? Types of IAC Abscess 2 peritonitis 1 peritonitis Infected pancreas Cholangitis IAC is more common than candidemia Vergidis ICAAC 2014 Diverse types of disease Overall mortality similar to candidemia 50% of cases did not have ID consult 29% of patients do not receive timely treatment with an antifungal agent Mortality: No antifungal 37% vs. antifungal 22%
43 Only 3% of Candida recovered from intra-abdominal candidiasis undergo susceptibility testing Vergidis % of patients with IAC who have received an echinocandin are infected with FKS mutant Candida Shields AAC 2014 Breakthrough: 50% Prolonged exposure (median: 119 vs 22 days) FKS mutant candidemia is often preceded by IAC MDR bacteria co-isolated in 83% of FKS mutant IAC Carbapenem-resistant K. pneumoniae Mortality rate for FKS mutant IAC 100% despite source control intervention
44 How can I take my clinical observations forward? Ryan Can we develop dosing regimens that optimize echinocandin efficacy and limit resistance? Paschalis Suboptimal PK at sites of IAC with conventional dosing is associated with treatment failures and resistance Can we understand the pathogenesis of IAC, and how it compares to the pathogenesis of other types of candidiasis? Candida gene expression patterns during IAC differ from other types of candidiasis, identify virulence determinants, and represent disease signatures
45 Cheng JID 2013 Cheng Infect Immun 2014
46 Site-specific caspofungin PK-PD Shields KO8 Echinocandin PK-PD within peritoneal fluid and abscesses HPLC-MS/MS PK modeling Hollow-fiber infection model in vitro to optimize PK-PD Validate regimens in mouse model Introduce optimized regimens in humans Echinocandin distribution within abscesses V. Darotis Mass spectometry imaging (MSI) New technology to directly visualize drug within infected tissues Can track unlabeled small molecules (i.e., drugs) temporally-spatially
47 C. albicans gene expression during IAC C. albicans nanostring nanostring profiling Probe sets included 145 C. albicans genes Control genes with high, medium and low expression Representative genes involved in antifungal responses, biofilm formation, hyphal growth, hypoxia, iron limitation, kidney infection, oxidative stress responses Transcription factors and protein kinases Peritoneal fluid harvested at 48 hours Data obtained in triplicate from 3 independently infected mice
48 C. albicans nanostring C. albicans gene expression during IAC Biological processes Genes Response to ph PHR1,RIM101, TEC1, ENA2, CAT1, GNP1, PHO89, RBT5, ARG1, FRP2. Response to polymorphonuclear cells DDR48, CAP1, FRP3, GCN4, TRR1, TRX1. CAT1, ENA21, GPD2, HOG1, HSP70, SSB1, Response to stress Adhesion Transporter Cellular process TRR1, TRX1, orf ALS1, ALS3, ALS4, SAP9, TDH3, TEC1 ENA21, ENA2, GNP1, SIT1, HGT7 GCN4, GPD2
49 C. albicans gene expression during human IAC Drain 2--- LUQ day 1 Drain 1--- RUQ day 1, RUQ day 2 (Fluconazole)
50 RNA-Seq C. albicans gene expression during human IAC RNA-Seq Illumina deep-sequencing technology (Bill Nierman, JCVI) Differentially expressed genes identified using the EdgeR Bioconductor package (Camille Mesline and Nathan Clark) RNA-Seq count was normalized between the different samples and replicates using TMM A gene was considered significantly differentially expressed if its corresponding false discovery rate (FDR) was and if its foldchange was 4
51 In the global comparison 3,406 genes were found to be differentially expressed between the different sample conditions at a FDR of 0.1% Replicates of each model clustered together: In vitro > ex vivo >> human and murine experiments results are reproducible for each experimental model Experiments using in vitro or ex vivo conditions are not very representative of the in vivo experiments
52 C. albicans C. albicans gene expression gene expression day 2 vs. day 1 RUQ-D2 vs RUQ-D1 and LUQ-D1 23% of genes were differentially expressed Up in RUQ-D2 (434 genes) Up in Day 1 samples (697 genes) Regulation of filamentous growth Adhesins, pathogenesis Ergosterol biosynthesis Nucleosome assembly, trna/ribosomal processing C3_01800C_A, CEK1, CHK1, CLA4, CLN3, CPH1, CPP1, CST20, CYR1, DEF1, EFG1, FLO8, KSP1, MDS3, MSB2, MSS11, MYO2, MYO5, NIK1, NRG1, OPY2, RFG1, RFX2, RGT1, RIM101, SET3, SFL1, SKN7, SSK1, ZCF10, ZCF16 ALS1, ALS3, CEK1, CLA4, CYR1, LPD1, NRG1, PHR2, RIM101, RVS164, etc. ERG3, ERG6, ERG10, ERG24, UPC2
53 In vitro Identify Candida genes that contribute to antifungal responses and pathogenesis Ex vivo Mouse or human IAC samples DC model (kidney) Identify expression signatures for diagnostics, prognosis, treatment responses or failures Profile host responses (RNA-Seq) Vergidis KL2 OPC model (tongue)
54 Research what you see Research what interests you clinically Once you ve asked a clinical question, you ve started a research project It s a good time to be entering I.D. research We need you Conclusions (2)
55 Acknowledgments UPMC Transplant ID and Antimicrobial Management Programs M. Hong Nguyen, MD (Director) Ryan Shields, PharmD Pascalis Vergidis, MD Greg Eschenauer, PharmD Brooke Decker, MD
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationDifficult to diagnose fungal infections: Non-fungaemic candidiasis
Difficult to diagnose fungal infections: Non-fungaemic candidiasis Director, Mycology Research Unit and XDR Pathogen Laboratory University of Pittsburgh Cornelius J. Clancy, M.D. Chief, Infectious Diseases
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationEUCAST-AFST Available breakpoints 2012
EUCAST-AFST Available breakpoints th NSMM meeting Göteborg, Sweden October th EUCAST-AFST documents Reference Methods Yeast E.DEF. () TN- E.DEF. (CMI epub July) E.DEF. () TN- E.DEF. () Breakpoints Compound
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationTissue Distribution/Penetration and Pharmacokinetics of CD101
Tissue Distribution/Penetration and Pharmacokinetics of CD0 Yanan Zhao, Brendan Prideaux, Pei-Yu Chen, Yoji Nagasaki, Min Hee Lee, Grayson Hough, Voon Ong, Veronique Dartois, David S. Perlin Public Health
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationESCMID Online Lecture Library. by author
What is the best antifungal strategy for severe intra-abdominal infections? Philippe Montravers MD, PhD Anaesthesia and Surgical ICU Bichat Claude Bernard Hospital Assistance Publique Hopitaux de Paris
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationAntifungal Drug Resistance: a Cause for Concern?
Antifungal Drug Resistance: a Cause for Concern? Sharon Chen Centre for Infectious Diseases and Microbiology CIDM-PH, CRE in Critical Infections, June 2014 Vis-à-vis bacteria - lesser scale and emotive
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More information2/6/14. What s Hot in ID Objectives
What s Hot in ID 2014 James S. Lewis II, Pharm.D., FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Portland, OR Objectives Describe highlights of the Interscience Conference
More informationRezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018
: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationReceived 6 October 2010/Returned for modification 26 December 2010/Accepted 7 January 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1580 1587 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01364-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More informationCD101: A Novel Echinocandin
CD101: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer TIMM Belgrade, Serbia October 8, 2017 1 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics 2 Cidara
More informationUpdates: Candida Epidemiology and Candida auris
National Center for Emerging and Zoonotic Infectious Diseases Updates: Candida Epidemiology and Candida auris Tom Chiller MD MPHTM Chief, Mycotic Diseases Branch My usual Disclosure! 1 Candidemia surveillance
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationThe Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver
S PECIAL A RTICLE The Evolving Role of Antifungal Susceptibility Testing Gregory A. Eschenauer and Peggy L. Carver Although increasing numbers of hospital microbiology laboratories are performing antifungal
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationAnidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies
Received: 1 February 2017 Revised: 11 May 2017 Accepted: 11 May 2017 DOI: 10.1111/myc.12641 ORIGINAL ARTICLE Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationSCY-078 ECMM Symposium Cologne, Germany October 2017
A New Path for Antifungal Treatments SCY-078 ECMM Symposium Cologne, Germany October 2017 David Angulo, M.D. Chief Medical Officer SCYNEXIS at a Glance Company created in 2000 Spin-off of Sanofi, initially
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAntifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units
Journal of Medical Microbiology (2012), 61, 389 393 DOI 10.1099/jmm.0.037895-0 Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian
More informationOslo meeting May 21st 2014
Oslo meeting May 21st 2014 Resistance mechanisms in fungal infections - in Denmark By Rasmus Hare Jensen PhD. student, Mycology Unit, Statens Serum Institut, Copenhagen, Denmark Disclosures 1 Talk divided
More informationInterlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?
AAC Accepts, published online ahead of print on 9 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01519-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationAntifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients
ISSN: 2319-7706 Volume 4 Number 3 (2015) pp. 716-720 http://www.ijcmas.com Original Research Article Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients Deepak Kumar 1, Sayan
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Shrutika Wandre et al. Special Issue, 2015, pp. 25-36 PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI Shrutika Wandre Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing,
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationESCMID Online Lecture Library. by author
Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationAntifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
REVIEW 10.1111/1469-0691.12495 Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside M. Cuenca-Estrella National Center for Microbiology, Instituto de Salud Carlos III, Madrid,
More informationCaspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3254 3260 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01750-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Caspofungin
More informationAPX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections
APX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections TIMM, Belgrade, Serbia October, 2017 New antifungal drugs in the pipeline S15 Dr. Michael Hodges
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationFigure S1 The glucosylceramide pathway mutants grow normally at neutral and alkaline ph Figure S2 Variability in the infectivity assay
A. List of Supplementary Figures and Tables Figure S1 The glucosylceramide pathway mutants grow normally at neutral and alkaline ph Figure S2 Variability in the infectivity assay Table S1 C. albicans mutants
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationEpidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients
OPEN (2017) 6, e87; doi:10.1038/emi.2017.74 www.nature.com/emi ORIGINAL ARTICLE Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients Ping-Feng
More informationon March 29, 2019 by guest
JCM Accepts, published online ahead of print on 4 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationTerapia empirica e mirata delle infezioni invasive da Candida
Terapia empirica e mirata delle infezioni invasive da Candida Francesco Menichetti, MD Head, Infectious Diseases Unit Ospedale Nuovo Santa Chiara Pisa, Italy Corso Avanzato di Terapia Antibiotica X Edizione
More informationCandida glabrata: an emerging pathogen in Brazilian tertiary care hospitals
Medical Mycology January 2013, 51, 38 44 Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals ARNALDO L. COLOMBO *, MARCIA GARNICA, LUIS FERNANDO ARANHA CAMARGO, CLOVIS ARNS DA CUNHA,
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationSupplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to
Supplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to Intra-abdominal Candida Infection in High Risk Surgical ICU Patients A. Wójtowicz, Ph.D. 1, F. Tissot, M.D.
More informationReducing the antifungal drugs consumption in the ICU
Reducing the antifungal drugs consumption in the ICU Philippe Montravers Département d Anesthésie et Réanimation Chirurgicale CHU Bichat Claude Bernard Pole TCAUR, HUPNVS Assistance Publique-Hôpitaux de
More informationReceived 25 March 2008/Returned for modification 12 May 2008/Accepted 15 June 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2008, p. 2620 2629 Vol. 46, No. 8 0095-1137/08/$08.00 0 doi:10.1128/jcm.00566-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Correlation
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationCandidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex ORIGINAL ARTICLE ABSTRACT Introduction: Although the spectrum of fungi causing bloodstream fungal infections
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Wandre et al., 2015 Volume 1 Issue 1, pp. 25-36 Year of Publication: 2015 DOI- https://dx.doi.org/10.20319/lijshls.2015.s11.2536 This paper can be cited as: Wandre, S., Sanap, S., Mukadam, T., Vaidya,
More informationNewer Combination Therapies
Newer Combination Therapies William J. Steinbach, MD Associate Professor of Pediatrics, Molecular Genetics & Microbiology Pediatric Infectious Diseases Duke University Medical Center Combination Therapy
More informationResistance epidemiology
ECMM/EFISG symposium: Multidrug resistance in fungi? A formidable foe Resistance epidemiology Ana Alastruey Izquierdo Mycology Reference Lab Spain Instituto de Salud Carlos III Disclousure I have received
More informationEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Journal of Antimicrobial Chemotherapy (2008) 62, 1094 1100 doi:10.1093/jac/dkn304 Advance Access publication 25 July 2008 Evaluation of aminocandin and caspofungin against Candida glabrata including isolates
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More information